Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

OBJECTIVES: To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: (90)Y-DOTATyr3- octreotide ((90)Y-DOTATOC) and (177)Lu-DOTA-Tyr3- octreotate ((177)Lu-DOTATATE). MATERIAL AND METHODS: The study included 5 patients with advanced NET referred to European centres for treatment with (90)Y-DOTATOC and (177)Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index. RESULTS: All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients. CONCLUSION: Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life.

Outcome of treating advanced neuroendocrine tumours with radiolabelled somatostatin analogues

OBJECTIVES: To evaluate the initial response and outcomes (quality of life and presence of side effects) in patients with advanced neuroendocrine tumours (NET) after treatment with radiolabelled somatostatin analogues: (90)Y-DOTATyr3- octreotide ((90)Y-DOTATOC) and (177)Lu-DOTA-Tyr3- octreotate ((177)Lu-DOTATATE). MATERIAL AND METHODS: The study included 5 patients with advanced NET referred to European centres for treatment with (90)Y-DOTATOC and (177)Lu-DOTATATE after lack of response to conventional treatment. The mean age was 45.6 years (29-68 years). Response to therapy was assessed according to: (1) RECIST criteria, as complete response, partial response, stable disease or disease progression, (2) post-treatment survival time and (3) quality of life, using the Karnofsky performance index. RESULTS: All patients survived for >20 months after treatment; mean survival time was 28 months. At the time of writing, three of the patients are alive after 20, 26 and 37 months. Partial response was observed in one patient, stable disease in three and disease progression in the fifth patient. A good-to-excellent post-treatment quality of life was observed in all patients. CONCLUSION: Therapy with radiolabelled somatostatin analogues showed promising results in patients with advanced NET, with a partial response or disease stabilisation in four of the five patients, who have enjoyed an extended survival period and an improved quality of life (AU)

No disponible

Granulomatosis linfomatoide: una entidad poco conocida / No disponible

Propósito: describir un caso clínico de granulomatosislinfomatoide, y realizar una revisión de labibliografía existente para conocer mejor dicha enfermedad.Material y métodos: varón de 27 años conantecedentes de linfoma no Hodgkin B a los 17años que debuta con insuficiencia respiratoria trasdiez años en revisiones periódicas.Conclusiones: la granulomatosis linfomatoideconstituye una entidad rara, de mal pronóstico y enla que no se ha definido el mejor tratamiento posible,existiendo diversas posibilidades y siendo necesarioun mayor estudio de dicha entidad con el finde mejorar su pronóstico

Purpose: To describe a clinical case of lymphomatoidgranulomatosis and to make a review ofthe existing bibliography for the better knowing ofthe disease.Material and methods: A 27 year old manwith a history of B-cell lymphoma at he age of 17years that started with respiratory insufficiency afterten years of periodic checkups.Conclusion: Lymphomatoid granulomatosis isa rare entity, with a poor prognosis and a lack of anestablished treatment. Although different treatmentshave been applied, further studies are necessary in order to improve its prognosis (AU)

Pioderma gangrenoso como síndrome paraneoplásico de un adenocarcinoma de recto / Gangrenous pyoderma as paraneoplastic syndrome of an adenocarnocima of the rectum

Propósito: Los síndromes paraneoplásicos sonentidades sintomáticas provocadas por el cáncer endiversos lugares del organismo. Su incidencia estáinfraestimada y no siempre son bien conocidos. Pretendemospresentar un ejemplo de los hechos quedebe cumplir una entidad nosológica para ser consideradacomo síndrome paraneoplásico: relacióntemporal y curso evolutivo paralelo.Material y métodos: Mujer de 72 años quedebuta con una lesión cutánea finalmente diagnosticadacomo pioderma gangrenoso precediendo a unaneoplasia digestiva.Conclusiones: El tumor digestivo más frecuentementeasociado al pioderma gangrenoso es elcolorectal. Se puede afirmar que está bien establecidala existencia de esta enfermedad cutánea comosíndrome paraneoplásico

Purpose: Paraneoplastic syndromes are clinicalsyndromes caused by tumors occurring in placesdistant from the tumor itself. Its incidence isunderestimated. We present a case of paraneoplasticsyndrome as an example, indicating thecharacteristics these syndromes must follow to beconsidered as suchMaterial and methods: A 72 year oldwoman with a skin disorder diagnosed as pyodermagangraenosum before the diagnosis of a colo-rectalcancer were made.Conclusion: Colo-rectal tumors are thedigestive neoplasms more frequently associated topyoderma. The relation between pyoderma as aparaneoplastic syndrome of colo-rectal cancer iswell established